T-DXd Plus Pertuzumab Outperforms Standard of Care for First-Line Treatment of Advanced HER2-Positive Breast Cancer
Adding Immune Checkpoint Inhibitor to Standard Chemotherapy Regimen Improves Outcomes in Stage 3 Colon Cancer, Study Finds
Diet Influences Survival After Stage III Colon Cancer, Dana-Farber Study Finds
ADC Combination Outperforms Standard Treatment of Advanced Triple-Negative Breast Cancer
EQUAL Study Launches Lung Cancer Screening Trial for People at High Risk
New Study Unveils Potential Therapeutic Pathways for Aggressive Pediatric Brain Tumor
Clinical Trial Offers CAR T-Cell Therapy Targeting MUC16 for Recurrent/Refractory Ovarian Cancer
Molecular Tripwires and Sponges Evolved in Bacterial Struggle for Survival
What is Immunopeptidomics?
New Insights into Immunotherapy Targets for Pancreatic Cancer
Chain Reaction: The Belzutifan Journey
Immunotherapy Before and After Surgery Improves Outcomes in Head and Neck Cancer
Head and Neck, Breast, Lung and Survivorship Studies Headline Dana-Farber Research at AACR Annual Meeting 2025
Effects of Immunotherapy Can Last After Treatment Stops According to Dana-Farber Study
Dana-Farber Researchers Receive AACR 2025 Scientific Achievement Awards
Showing 61 - 75 of 987 results
Previous| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ...66 |Next
Cancer
Cardiology
Gastroenterology
Neurology
OBGYN
Orthopedics
Pediatrics
BroadcastMed News
Dermatology
Diabetes & Endocrinology
Infectious Diseases
Ophthalmology
Optometry
Otolaryngology
Pulmonology
Surgery
Urology
About
Solutions
Resources
Contact
person Sign In / Create Account
